KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 190 filers reported holding KITE PHARMA INC in Q4 2015. The put-call ratio across all filers is 0.66 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $736,143,000 | +77.6% | 4,094,002 | +2.4% | 0.03% | +70.0% |
| Q2 2017 | $414,501,000 | +44.2% | 3,998,269 | +9.2% | 0.02% | +33.3% |
| Q1 2017 | $287,395,000 | +103.2% | 3,661,547 | +16.1% | 0.02% | +87.5% |
| Q4 2016 | $141,437,000 | -16.5% | 3,154,258 | +4.0% | 0.01% | -20.0% |
| Q3 2016 | $169,487,000 | +15.5% | 3,034,136 | +3.4% | 0.01% | +11.1% |
| Q2 2016 | $146,771,000 | +15.8% | 2,935,406 | +6.3% | 0.01% | +12.5% |
| Q1 2016 | $126,782,000 | -21.7% | 2,761,527 | +5.0% | 0.01% | -27.3% |
| Q4 2015 | $162,020,000 | -31.5% | 2,629,342 | -38.1% | 0.01% | +22.2% |
| Q3 2015 | $236,444,000 | +137.8% | 4,246,476 | +160.4% | 0.01% | +28.6% |
| Q2 2015 | $99,415,000 | +13.4% | 1,630,554 | +7.3% | 0.01% | +16.7% |
| Q1 2015 | $87,689,000 | +109.3% | 1,520,269 | +109.3% | 0.01% | +100.0% |
| Q4 2014 | $41,890,000 | +192.3% | 726,363 | +44.5% | 0.00% | +200.0% |
| Q3 2014 | $14,330,000 | – | 502,820 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |